R. Grotzfeld

发表

A small molecule–kinase interaction map for clinical kinase inhibitors

L. Wodicka, D. Lockhart, P. Zarrinkar, 2005, Nature Biotechnology.

Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay.

J. Mestan, D. Fabbro, W. Jahnke, 2010, Journal of the American Chemical Society.

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.

F. Lombardo, D. Fabbro, W. Jahnke, 2018, Journal of medicinal chemistry.

Discovery of Potent and Selective Antibody-Drug Conjugates with Eg5 Inhibitors through Linker and Payload Optimization.

M. P. Dillon, R. Grotzfeld, Edward G. Lorenzana, 2019, ACS medicinal chemistry letters.

Methodology for optimizing functional miniature proteins based on avian pancreatic polypeptide using phage display.

J. Chin, M. A. Fabian, R. Grotzfeld, 2001, Bioorganic & medicinal chemistry letters.

Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.

P. Zarrinkar, H. Patel, T. Carter, 2009, Journal of medicinal chemistry.

Reversible Encapsulation of Disc-Shaped Guests by a Synthetic, Self-Assembled Host

R. Grotzfeld, J. Rebek, N. Branda, 1996, Science.

CONTROL OF SELF-ASSEMBLY AND REVERSIBLE ENCAPSULATION OF XENON IN A SELF-ASSEMBLING DIMER BY ACID-BASE CHEMISTRY

Julius Rebek, R. Grotzfeld, J. Rebek, 1995 .

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.

William Pao, Harold Varmus, Daniel K Treiber, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site.

Wolfgang Jahnke, Doriano Fabbro, Pascal Furet, 2010, Biochimica et biophysica acta.

ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia

W. Sellers, F. Lombardo, W. Jahnke, 2014 .

Modular synthesis and modification of novel bifunctional dendrons.

R. Grotzfeld, Cameron C. Lee, Daniela Miranda, 2019, Organic & biomolecular chemistry.

Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.

P. Zarrinkar, H. Patel, T. Carter, 2009, Journal of medicinal chemistry.

Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site.

J. Mestan, D. Fabbro, W. Jahnke, 2010, Biochimica et biophysica acta.

Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitors.

D. Lockhart, P. Zarrinkar, D. K. Treiber, 2009, Bioorganic & medicinal chemistry letters.